Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
NCT00019539 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019539 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer |
| Official title | Phase II Randomized Study of Monoclonal Antibody VEGF in Patients With Unresectable Advanced Renal Cell Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab, thalidomide |
| Start date | Nov 1, 1998 |
| Completion | Nov 1, 2004 |
| First posted | Jan 13, 2009 |
| Last update posted | Mar 4, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: